Shuchi Gulati1, Ulka Vaishampayan2. 1. University of Cincinnati, Cincinnati, OH, USA. 2. Wayne State University Detroit, 4100 John R, Detroit, MI, 48201, USA. vaishamu@gmail.com.
Abstract
PURPOSE OF REVIEW: Due to the rapidly changing field of kidney cancer therapeutics, addressing the state of the art systemic therapy regimens, and sequencing with cytoreductive nephrectomy are the primary focus of this review. We will also discuss the role of biomarkers and novel therapeutic targets in the management of renal cell carcinoma. RECENT FINDINGS: The management of metastatic renal cell cancer has undergone a paradigm shift with immune checkpoint inhibitors being used in the frontline setting. Over the last 4 years, programmed cell death-1 (PD-1) inhibitors as well as programmed cell death ligand-1 inhibitors have become available in various combinations with cytotoxic T lymphocyte-associated protein-4 (CTLA-4) inhibitors and tyrosine kinase inhibitors (TKIs). These drugs have improved outcomes in patients with renal cell cancer and more work is being done to refine these targets as well as discover newer ones. Despite the availability of several new treatment options, some questions that still need to be addressed in the management of kidney cancer include the sequencing of treatment options, treatment of patients who progress on immune checkpoint inhibitors, and role of biomarkers to ascertain the best treatment options to minimize costs and improve outcomes.
PURPOSE OF REVIEW: Due to the rapidly changing field of kidney cancer therapeutics, addressing the state of the art systemic therapy regimens, and sequencing with cytoreductive nephrectomy are the primary focus of this review. We will also discuss the role of biomarkers and novel therapeutic targets in the management of renal cell carcinoma. RECENT FINDINGS: The management of metastatic renal cell cancer has undergone a paradigm shift with immune checkpoint inhibitors being used in the frontline setting. Over the last 4 years, programmed cell death-1 (PD-1) inhibitors as well as programmed cell death ligand-1 inhibitors have become available in various combinations with cytotoxic T lymphocyte-associated protein-4 (CTLA-4) inhibitors and tyrosine kinase inhibitors (TKIs). These drugs have improved outcomes in patients with renal cell cancer and more work is being done to refine these targets as well as discover newer ones. Despite the availability of several new treatment options, some questions that still need to be addressed in the management of kidney cancer include the sequencing of treatment options, treatment of patients who progress on immune checkpoint inhibitors, and role of biomarkers to ascertain the best treatment options to minimize costs and improve outcomes.
Authors: Andrew J Armstrong; Susan Halabi; Tim Eisen; Samuel Broderick; Walter M Stadler; Robert J Jones; Jorge A Garcia; Ulka N Vaishampayan; Joel Picus; Robert E Hawkins; John D Hainsworth; Christian K Kollmannsberger; Theodore F Logan; Igor Puzanov; Lisa M Pickering; Christopher W Ryan; Andrew Protheroe; Christine M Lusk; Sadie Oberg; Daniel J George Journal: Lancet Oncol Date: 2016-01-13 Impact factor: 41.316
Authors: Robert J Motzer; Thomas E Hutson; Hilary Glen; M Dror Michaelson; Ana Molina; Timothy Eisen; Jacek Jassem; Jakub Zolnierek; Jose Pablo Maroto; Begoña Mellado; Bohuslav Melichar; Jiri Tomasek; Alton Kremer; Han-Joo Kim; Karen Wood; Corina Dutcus; James Larkin Journal: Lancet Oncol Date: 2015-10-22 Impact factor: 41.316
Authors: M Ivan; K Kondo; H Yang; W Kim; J Valiando; M Ohh; A Salic; J M Asara; W S Lane; W G Kaelin Journal: Science Date: 2001-04-05 Impact factor: 47.728
Authors: S Yasuda; M Sho; I Yamato; H Yoshiji; K Wakatsuki; S Nishiwada; H Yagita; Y Nakajima Journal: Clin Exp Immunol Date: 2013-06 Impact factor: 4.330
Authors: Axel Bex; Peter Mulders; Michael Jewett; John Wagstaff; Johannes V van Thienen; Christian U Blank; Roland van Velthoven; Maria Del Pilar Laguna; Lori Wood; Harm H E van Melick; Maureen J Aarts; J B Lattouf; Thomas Powles; Igle Jan de Jong Md PhD; Sylvie Rottey; Bertrand Tombal; Sandrine Marreaud; Sandra Collette; Laurence Collette; John Haanen Journal: JAMA Oncol Date: 2019-02-01 Impact factor: 31.777
Authors: Qiangmin Qiu; Yanze Li; Ye Zhang; Yanguang Hou; Juncheng Hu; Lei Wang; Zhiyuan Chen; Yourong Lei; Yang Du; Xiuheng Liu Journal: Front Med (Lausanne) Date: 2022-08-09
Authors: G Tsironis; M Liontos; A Kyriazoglou; K Koutsoukos; A Tsiara; M Kaparelou; R Zakopoulou; A Cohen; E Skafida; S Fontara; F Zagouri; A Bamias; M A Dimopoulos Journal: BMC Urol Date: 2020-06-02 Impact factor: 2.264
Authors: Ulka Vaishampayan; Harsh Shah; Mohammad F Asad; Dongping Shi; Brenda Dickow; Stacey Suisham; Jason Domina; Michael L Cher; Julie Samantray; Hussein D Aoun Journal: J Kidney Cancer VHL Date: 2020-10-12
Authors: Maria F Czyzyk-Krzeska; Julio A Landero Figueroa; Shuchi Gulati; John T Cunningham; Jarek Meller; Behrouz ShamsaeI; Bhargav Vemuri; David R Plas Journal: Genes (Basel) Date: 2021-03-09 Impact factor: 4.096